Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
Table 1
Combination index for the combination of trametinib and PI3K/mTOR inhibitors in three cell lines tested.